143 related articles for article (PubMed ID: 22449779)
21. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
Speiser DE; Romero P
Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326
[TBL] [Abstract][Full Text] [Related]
22. A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis.
Liu B; Ye D; Song X; Zhao X; Yi L; Song J; Zhang Z; Zhao Q
Vaccine; 2008 Mar; 26(10):1387-96. PubMed ID: 18272260
[TBL] [Abstract][Full Text] [Related]
23. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA.
Velders MP; McElhiney S; Cassetti MC; Eiben GL; Higgins T; Kovacs GR; Elmishad AG; Kast WM; Smith LR
Cancer Res; 2001 Nov; 61(21):7861-7. PubMed ID: 11691804
[TBL] [Abstract][Full Text] [Related]
24. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
[TBL] [Abstract][Full Text] [Related]
25. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
26. Human papillomavirus vaccines.
Breitburd F; Coursaget P
Semin Cancer Biol; 1999 Dec; 9(6):431-44. PubMed ID: 10712890
[TBL] [Abstract][Full Text] [Related]
27. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
[TBL] [Abstract][Full Text] [Related]
28. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16.
He Z; Wlazlo AP; Kowalczyk DW; Cheng J; Xiang ZQ; Giles-Davis W; Ertl HC
Virology; 2000 Apr; 270(1):146-61. PubMed ID: 10772987
[TBL] [Abstract][Full Text] [Related]
29. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review.
Girard MP; Osmanov S; Assossou OM; Kieny MP
Vaccine; 2011 Aug; 29(37):6191-218. PubMed ID: 21718747
[TBL] [Abstract][Full Text] [Related]
30. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
Fiorentini S; Marini E; Bozzo L; Trainini L; Saadoune L; Avolio M; Pontillo A; Bonfanti C; Sarmientos P; Caruso A
Biopolymers; 2004; 76(4):334-43. PubMed ID: 15386266
[TBL] [Abstract][Full Text] [Related]
31. DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection.
Brulet JM; Maudoux F; Thomas S; Thielemans K; Burny A; Leo O; Bex F; Hallez S
Eur J Immunol; 2007 Feb; 37(2):376-84. PubMed ID: 17274002
[TBL] [Abstract][Full Text] [Related]
32. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J
Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411
[TBL] [Abstract][Full Text] [Related]
33. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
34. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.
Welters MJ; Kenter GG; de Vos van Steenwijk PJ; Löwik MJ; Berends-van der Meer DM; Essahsah F; Stynenbosch LF; Vloon AP; Ramwadhdoebe TH; Piersma SJ; van der Hulst JM; Valentijn AR; Fathers LM; Drijfhout JW; Franken KL; Oostendorp J; Fleuren GJ; Melief CJ; van der Burg SH
Proc Natl Acad Sci U S A; 2010 Jun; 107(26):11895-9. PubMed ID: 20547850
[TBL] [Abstract][Full Text] [Related]
35. Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization.
Berzofsky JA
Biotechnol Ther; 1991; 2(1-2):123-35. PubMed ID: 1726961
[TBL] [Abstract][Full Text] [Related]
36. HIV vaccines: a brief overview.
Lema D; Garcia A; De Sanctis JB
Scand J Immunol; 2014 Jul; 80(1):1-11. PubMed ID: 24813074
[TBL] [Abstract][Full Text] [Related]
37. Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome.
Voskens CJ; Strome SE; Sewell DA
Curr Mol Med; 2009 Aug; 9(6):683-93. PubMed ID: 19689295
[TBL] [Abstract][Full Text] [Related]
38. Design of synthetic peptidic constructs for the vaccine development against viral infections.
Haro I; Gómara MJ
Curr Protein Pept Sci; 2004 Dec; 5(6):425-33. PubMed ID: 15581414
[TBL] [Abstract][Full Text] [Related]
39. Progress in the development of a preventive HIV-1 vaccine.
Elizaga ML; McElrath MJ
Clin Lab Med; 2002 Dec; 22(4):963-80, vii. PubMed ID: 12489290
[TBL] [Abstract][Full Text] [Related]
40. HIV-1 vaccine design: harnessing diverse lymphocytes to conquer a diverse pathogen.
Surman SL; Sealy R; Jones BG; Hurwitz JL
Hum Vaccin; 2009 Apr; 5(4):268-71. PubMed ID: 19684481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
